Scarica l'app Stockscreener
1.635
2.98%
-0.045
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZNTL Giù?
Forum
Previsione
Precedente Chiudi:
$1.68
Aprire:
$1.7
Volume 24 ore:
359.51K
Relative Volume:
0.53
Capitalizzazione di mercato:
$117.58M
Reddito:
-
Utile/perdita netta:
$-292.19M
Rapporto P/E:
-0.3601
EPS:
-4.54
Flusso di cassa netto:
$-208.41M
1 W Prestazione:
+2.52%
1M Prestazione:
+9.40%
6M Prestazione:
+32.52%
1 anno Prestazione:
-45.48%
Intervallo 1D:
$1.61
$1.715
Intervallo di 1 settimana:
$1.53
$1.84
Portata 52W:
$1.01
$4.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Nome
Zentalis Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 263-4333
Indirizzo
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Confronta ZNTL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.63 | 121.19M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.45 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.07 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-12 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2024-06-20 | Downgrade | UBS | Buy → Neutral |
| 2024-06-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-06-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Downgrade | Wedbush | Neutral → Underperform |
| 2024-06-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-11-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Iniziato | Cowen | Outperform |
| 2022-04-06 | Iniziato | Wells Fargo | Overweight |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-29 | Iniziato | Oppenheimer | Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-01-20 | Iniziato | Wedbush | Outperform |
| 2020-09-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-28 | Iniziato | Guggenheim | Buy |
| 2020-04-28 | Iniziato | Jefferies | Buy |
| 2020-04-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Zentalis Pharmaceuticals Inc Borsa (ZNTL) Ultime notizie
How Zentalis Pharmaceuticals Inc. stock benefits from strong dollarGap Up & Stepwise Entry and Exit Trade Signals - newser.com
How currency fluctuations impact Zentalis Pharmaceuticals Inc. stockWall Street Watch & Risk Managed Investment Signals - newser.com
Will Zentalis Pharmaceuticals Inc. stock keep outperforming rivalsJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress - ADVFN Ltd
Can Zentalis Pharmaceuticals Inc. hit a new high this monthTrade Risk Summary & Weekly High Potential Stock Alerts - newser.com
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Wealth Enhancement Advisory Services LLC - Defense World
What institutional flow reveals about Zentalis Pharmaceuticals Inc.Market Sentiment Review & Community Trade Idea Sharing - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
What earnings revisions data tells us about Zentalis Pharmaceuticals Inc.Weekly Trade Report & Entry Point Confirmation Alerts - newser.com
Full technical analysis of Zentalis Pharmaceuticals Inc. stockJuly 2025 Review & AI Optimized Trade Strategies - newser.com
Using data filters to optimize entry into Zentalis Pharmaceuticals Inc.Watch List & Verified Technical Trade Signals - newser.com
Zentalis Pharmaceuticals' (ZNTL) "Sell (E+)" Rating Reiterated at Weiss Ratings - MarketBeat
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock - Yahoo Finance
Key metrics from Zentalis Pharmaceuticals Inc.’s quarterly dataQuarterly Market Summary & Stepwise Swing Trade Plans - newser.com
Short interest data insights for Zentalis Pharmaceuticals Inc.2025 Fundamental Recap & Verified Short-Term Plans - newser.com
Pattern recognition hints at Zentalis Pharmaceuticals Inc. upsideJuly 2025 Review & Target Return Focused Picks - newser.com
How to build a dashboard for Zentalis Pharmaceuticals Inc. stockMarket Activity Report & Smart Swing Trading Techniques - newser.com
Positive week for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional investors who lost 48% over the past year - simplywall.st
What analysts say about Zentalis Pharmaceuticals Inc stockDebt-to-Equity Ratio Analysis & Ride the Trends That Billionaires Follow - earlytimes.in
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
400,000 Stock Options at $1.54: Zentalis Pharmaceuticals Welcomes New Chief Legal Officer with Major Grant - Stock Titan
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Goldman Sachs Group Inc. - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Zentalis Pharmaceuticals Inc Azioni (ZNTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Zentalis Pharmaceuticals Inc Azioni (ZNTL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):